Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 4 de 4
Filter
Add more filters










Database
Language
Publication year range
1.
Acta Crystallogr D Struct Biol ; 75(Pt 6): 523-527, 2019 Jun 01.
Article in English | MEDLINE | ID: mdl-31205014

ABSTRACT

Michael George Rossmann, who made monumental contributions to science, passed away peacefully in West Lafayette, Indiana on 14 May 2019 at the age of 88, following a courageous five-year battle with cancer. Michael was born in Frankfurt, Germany on 30 July 1930. As a young boy, he emigrated to England with his mother just as World War II ignited. Michael was a highly innovative and energetic person, well known for his intensity, persistence and focus in pursuing his research goals. Michael was a towering figure in crystallography as a highly distinguished faculty member at Purdue University for 55 years. Michael made many seminal contributions to crystallography in a career that spanned the entirety of structural biology, beginning in the 1950s at Cambridge where the first protein structures were determined in the laboratories of Max Perutz (hemoglobin, 1960) and John Kendrew (myoglobin, 1958). Michael's work was central in establishing and defining the field of structural biology, which amazingly has described the structures of a vast array of complex biological molecules and assemblies in atomic detail. Knowledge of three-dimensional biological structure has important biomedical significance including understanding the basis of health and disease at the molecular level, and facilitating the discovery of many drugs.


Subject(s)
Crystallography/history , Macromolecular Substances/history , Viruses/ultrastructure , Awards and Prizes , History, 20th Century , Humans , Macromolecular Substances/ultrastructure
3.
J Control Release ; 190: 288-303, 2014 Sep 28.
Article in English | MEDLINE | ID: mdl-24747162

ABSTRACT

This review covers water-soluble polymer-drug conjugates and macromolecules that possess biological activity without attached low molecular weight drugs. The main design principles of traditional and backbone degradable polymer-drug conjugates as well as the development of a new paradigm in nanomedicines - (low molecular weight) drug-free macromolecular therapeutics are discussed. To address the biological features of cancer, macromolecular therapeutics directed to stem/progenitor cells and the tumor microenvironment are deliberated. Finally, the future perspectives of the field are briefly debated.


Subject(s)
Drug Carriers , Macromolecular Substances , Neoplasms/drug therapy , Polymers , Drug Carriers/history , Drug Design , History, 20th Century , Humans , Macromolecular Substances/chemistry , Macromolecular Substances/history , Neoplasms/pathology , Polymers/chemistry , Polymers/history , Solubility , Stem Cells
SELECTION OF CITATIONS
SEARCH DETAIL
...